Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

NCT04248621 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

164

Enrollment

OTHER

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Leuprorelin
DRUG: Goserelin
DRUG: Triptorelin
DRUG: Degarelix
DRUG: Bicalutamide
DRUG: Flutamide
DRUG: Maximum androgen blockade

Sponsor

Wonju Severance Christian Hospital

Collaborators

[object Object]